Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2017/02/007836
CTRI/2017/02/007836Other未知

A single arm, open label, multicentric, clinical study assessing the efficacy and safety of intramuscular administration of stempeucel® (ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells) in patients with critical limb ischemia due to Buergerâ??s Disease

Stempeutics Research Pvt Ltd0 sites164 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Other
Enrollment
164
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •a.Buergerâ??s disease as diagnosed by Shionoya criteria
  • •b.Males or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 yrs.
  • •c.Established CLI in the study limb, clinically and hemodynamically confirmed as per Rutherford- III-5;
  • •d.Patients in Rutherford- III-6 if gangrene extending maximally up to the head of metatarsal but limited to toes (patients with wet gangrene must undergo wound debridement / amputation before screening).
  • •e.Patients having infrapopliteal occlusive disease with rest pain and ischemic ulcer/necrosis (patients should have at least one measureable ulcer), who are not eligible for or have failed traditional revascularization treatment as per the investigators judgment (No option patients).
  • •f.ABPI <= 0.6 or ankle pressure <= 50 mm Hg.
  • •g.Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent and video consent, abide by the study requirements, and agree to return for required follow-up visits.

Exclusion Criteria

  • •a.Patients with CLI indicated for major amputation during screening
  • •b.Atherosclerotic PAD
  • •c.Ulcers with exposure of tendon and/bone in the shin region.
  • •d.Previous above trans metatarsal amputation in study limb
  • •e.Any Lumbar sympathectomy procedure performed less than 90 days prior to the screening
  • •f.Patients with gait disturbance for reasons other than CLI
  • •g.Diagnosis of diabetes mellitus (type 1 or type 2)
  • •h.Patients having left ventricular ejection fraction < 35%
  • •i.Patients suffering from clinically relevant peripheral neuropathy
  • •j.History of stroke or myocardial infarction
  • •k.Patients who are contraindicated for MRA
  • •l.Patients with DVT in any limb.
  • •m.Patients who have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy
  • •n.Documented terminal illness or cancer or any concomitant disease process with a life expectancy of <1 year
  • •o.Patients already enrolled in another investigational drug trial or completed within 3 months or those who have received stem cells in the past
  • •p.Patient with known hypersensitivity to the constituents of the stempeucel®â?? dimethyl sulfoxide (DMSO) or human serum albumin (HSA)
  • •q.History of severe alcohol or drug abuse within 3 months of screening
  • •r.Hb% < 10 gm% for males, Hb% < 9 gm% for females, serum creatinine >= 2mg%, serum Total Bilirubin >=2mg%
  • •s.Pregnant and lactating women
  • •t.Patients tested positive for HIV 1 & 2, HCV, HBV, CMV, RPR antibodies and for HBsAg antigen

Investigators

Similar Trials

Active, not recruiting
Unknown
A study to assess the safety and effectiveness of toothpaste in human subjects with diabetes
CTRI/2023/09/057700Himalaya Wellness Company
Not yet recruiting
Phase 4
A Clinical Investigation study in Indian population to evaluate the Safety and Efficacy of Los DelineTM for contour & volume correction of Human Soft Tissues.
CTRI/2023/09/057513JCP International Private Limited
Completed
Phase 4
Treatment of dry or productive cough
CTRI/2020/03/023788Virgo UAP Pharma Pvt52
Completed
Phase 4
A prospective, multicentre, open-label, single armobservational study of Concor&reg; treatment in Asian patientswith Essential Hypertensio
CTRI/2010/091/002813Merck Pte Ltd3 International Business Park #02-01Nordic European CentreSingapore 6099271,000
Active, not recruiting
Not Applicable
To study the effect of Ischemia Reversal Program (IRP) along with diet modification for subjects suffering Coronary Artery Disease (CAD).
CTRI/2020/01/022814Vaidya Sane Ayurvedic Lab Pvt Ltd